Extensive-Stage Small Cell Lung Cancer
Conditions
Interventions
Observation group:None
Sponsors
Cancer Hospital Affiliated of Shandong First Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically or cytologically confirmed extensive-stage small cell lung cancer; 2. Receiving adebelimab-based therapy; 3. Subjects voluntarily joined this study, signed the informed consent form, had good compliance, and cooperated with follow-up.
Exclusion criteria
Exclusion criteria: 1. Prior treatment with any T cell co-stimulation or immune checkpoint therapy, including but not limited to cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitors, PD-1 inhibitors, PD-L1/2 inhibitors, or other drugs targeting T cells; 2. Patients who are participating in other interventional studies; 3. Patients with other malignant tumors at the same time; 4. Confirmed pregnancy and lactating females.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety;Duration of Response;Progression-Free Survival;Overall Survive; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate;Disease Control Rate; | — |
Countries
China
Contacts
Public ContactMeng Xiangjiao
Cancer Hospital Affiliated of Shandong First Medical University
Outcome results
None listed